Anchiano Therapeutics Ltd (ANCN) and Cellectis S.A. (NASDAQ:CLLS) Comparing side by side

We are comparing Anchiano Therapeutics Ltd (NASDAQ:ANCN) and Cellectis S.A. (NASDAQ:CLLS) on their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anchiano Therapeutics Ltd 6 0.00 N/A -5.26 0.00
Cellectis S.A. 17 37.26 N/A -1.62 0.00

In table 1 we can see Anchiano Therapeutics Ltd and Cellectis S.A.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 demonstrates the return on equity, net margins and return on assets of Anchiano Therapeutics Ltd and Cellectis S.A.

Net Margins Return on Equity Return on Assets
Anchiano Therapeutics Ltd 0.00% 0% 0%
Cellectis S.A. 0.00% 0% 0%

Analyst Ratings

Recommendations and Ratings for Anchiano Therapeutics Ltd and Cellectis S.A. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Anchiano Therapeutics Ltd 0 0 2 3.00
Cellectis S.A. 0 0 1 3.00

Anchiano Therapeutics Ltd has a consensus target price of $14, and a 381.10% upside potential. Meanwhile, Cellectis S.A.’s average target price is $38.67, while its potential upside is 155.75%. The results provided earlier shows that Anchiano Therapeutics Ltd appears more favorable than Cellectis S.A., based on analyst view.

Insider and Institutional Ownership

Roughly 0.75% of Anchiano Therapeutics Ltd shares are held by institutional investors while 34% of Cellectis S.A. are owned by institutional investors. 23.87% are Anchiano Therapeutics Ltd’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Anchiano Therapeutics Ltd -4.99% -11.11% 0% 0% 0% -47.66%
Cellectis S.A. -3.25% -4.03% 11.65% -28.06% -32.66% 14.53%

For the past year Anchiano Therapeutics Ltd has -47.66% weaker performance while Cellectis S.A. has 14.53% stronger performance.


Cellectis S.A. beats Anchiano Therapeutics Ltd on 5 of the 6 factors.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.